Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid.
A controlled clinical trial of epsilon-aminocaproic acid (E.A.C.A.), 36 g/day, was undertaken to assess its effectiveness in reducing immediate recurrence in patients with spontaneous subarachnoid haemorrhage (S.A.H.) proved by lumbar puncture. Of 83 patients treated with E.A.C.A., 3 (4%) had recurrent haemorrhage, and 1 (33%) of these died. Of 82 control patients who were not given any antifibrinolytic drug, 22 (26%) had recurrent haemorrhage, and 10 (45%) of these patients died. E.A.C.A. produced a striking reduction in the early recurrence of S.A.H. No serious side-effect resulted.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D001164:Arteriovenous Fistula / Q000150:complications; D001488:Basilar Artery; D002340:Carotid Artery Diseases / Q000150:complications; D002343:Carotid Artery, Internal; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012422:Rupture, Spontaneous; D013345:Subarachnoid Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D014711:Vertebral Artery
D000614:Aminocaproates; D015119:Aminocaproic Acid